BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive Day 90 data for the first patient from the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D). This is the first demonstration of a patient with T1D achieving robust restoration of islet cell function from such a cell therapy.
The patient was treated with a single infusion of VX-880 at half the target dose in conjunction with immunosuppressive therapy. The patient achieved successful engraftment and demonstrated rapid and robust improvements in multiple measures, including increases in fasting and stimulated C-peptide, improvements in glycemic control, including HbA1c, and decreases in exogenous insulin requirement. VX-880 was generally well tolerated.
These results from the first patient treated with VX-880 are unprecedented. What makes these results truly remarkable is that they were achieved with treatment at half the target dose, said Bastiano Sanna, Ph.D., Executive Vice President and Chief of Cell and Genetic Therapies at Vertex. While still early, these results support the continued progression of our VX-880 clinical studies, as well as future studies using our encapsulated islet cells, which hold the potential to be used without the need for immunosuppression.
As a surgeon who has worked in the field of islet cell transplantation for decades, this approach, which obviates the need for an organ donor, could be a game changer, said James Markmann, M.D., Ph.D., Professor of Surgery and Chief of the Division of Transplant Surgery at Massachusetts General Hospital. We are excited to progress this unique and potentially transformative medicine through clinical trials and to patients.
More than a decade ago our lab had a vision for developing an islet cell replacement therapy to provide a functional cure to people suffering from T1D, said Doug Melton, Ph.D., Xander University Professor at Harvard and an Investigator of the Howard Hughes Medical Institute. These promising results bring great hope that stem cell-derived, fully differentiated islet cells could deliver a life-changing therapy for people who suffer from the relentless life-long burden of T1D.
The patient was diagnosed with T1D approximately 40 years ago and has been dependent on exogenous insulin. In the one year prior to treatment, the patient experienced 5 severe, potentially life-threatening hypoglycemic episodes. Prior to treatment with VX-880, the patients insulin dose was 34 units per day and fasting and stimulated C-peptide levels were undetectable, indicating that the patient was not making their own insulin. Per the study protocol, the patient received half the target dose of VX-880 through a hepatic portal vein infusion in combination with a standard regimen of immunosuppressive agents.
Fasting C-peptide, HbA1c and 7-day average daily insulin dose were measured at various intervals after VX-880 treatment through Day 90. Fasting C-peptide was detected early after treatment with VX-880 and increased rapidly to Day 90. In parallel, HbA1c and daily insulin dose decreased over time.
Islet cell function was evaluated at baseline and at Day 90 using a Mixed Meal Tolerance Test (MMTT) with quantification of C-peptide levels, a direct marker for insulin production. At baseline prior to VX-880 treatment, fasting and stimulated C-peptide levels were undetectable, indicating no endogenous insulin production. At Day 90 after VX-880 treatment, fasting C-peptide was 280 pmol/L, reflecting restored basal insulin production and increased after MMTT stimulation to a peak of 560 pmol/L, indicating that VX-880 restored glucose-responsive insulin production. Also at Day 90, HbA1c improved from 8.6% at baseline to 7.2%, and daily insulin dose decreased from 34 units per day prior to treatment with VX-880 to an average dose of 2.9 units per day over a 7-day period at the Day 90 visit, reflecting a 91% decrease in daily exogenous insulin use.
Baseline and Day 90 Measures of Islet Cell Function for Patient 1
Day 90 after
Fasting C-peptide (pmol/L)
Peak Stimulated C-peptide with MMTT (pmol/L)
Daily insulin dose (units/day)**
*The lower limit of quantitation of the C-peptide assay is 13 pmol/L.**Daily insulin dose for baseline was measured on Day -3 prior to VX-880 infusion. For Day 90 post-infusion, average daily insulin dose was calculated over a 7-day period.
In this first patient, the safety of VX-880 was generally consistent with the immunosuppressive regimen used in this study. There were no serious adverse events (SAE) considered related to VX-880, and the majority of the adverse events were considered mild to moderate. The most common adverse events were severe hypoglycemic events, which were non-serious, not related to VX-880, and occurred in the perioperative period. Through Day 90, the patient had one SAE; this was a rash that was mild in severity, not related to VX-880, and resolved.
Based upon these data, Vertex plans to continue to progress the Phase 1/2 program for VX-880. There are multiple active sites in the U.S., and the Clinical Trial Application has been approved in Canada. Vertex is also progressing IND-enabling studies for its encapsulated islet cell program, which would potentially eliminate the requirement for immunosuppression, and plans to file an IND for this program in 2022.
VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. VX-880 is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 has the potential to restore the bodys ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose responsive insulin production. VX-880 is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection.
About the Phase 1/2 Clinical Trial
The clinical trial is a Phase 1/2, multi-center, single-arm, open-label study in patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. This study is designed as a sequential, multi-part clinical trial to evaluate the safety and efficacy of VX-880. The first two patients will be treated with half the target dose, followed by dose escalation to the target dose in the subsequent patients. Approximately 17 patients will be enrolled in the clinical trial. Enrollment is ongoing in this study.
About Type 1 Diabetes
T1D results from the autoimmune destruction of insulin-producing islet cells in the pancreas, leading to loss of insulin production and impairment of blood glucose control. The absence of insulin leads to abnormalities in how the body processes nutrients, leading to high blood glucose levels. High blood glucose can lead to diabetic ketoacidosis and over time, to complications such as kidney disease/failure, eye disease (including vision loss), heart disease, stroke, nerve damage and even death.
Due to the limitations and complexities of insulin delivery systems, it can be difficult to achieve and maintain balance in glucose control in patients with T1D. Hypoglycemia often results because of the difficulty in balancing the different factors that impact glucose levels, including insulin, diet and exercise. Hypoglycemia remains a critical limiting factor in glycemic management, and severe hypoglycemia can cause loss of consciousness, coma, seizures, injury, and can be fatal. Over time, patients with T1D can develop impaired awareness of hypoglycemia, meaning they are no longer able to perceive the early signs of a hypoglycemic event, which can be dangerous and result in life threatening events.
Current standards of care do not address the underlying causes of the disease, and there are limited treatment options beyond insulin for the management of T1D.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) a rare, life-threatening genetic disease and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex's history of innovation, visit http://www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Bastiano Sanna, Ph.D., Dr. James Markmann, and Doug Melton, Ph.D. in this press release, (ii) our plans, expectations for, and the potential benefits of VX-880, (iii) our plans to continue to progress the Phase 1/2 program for VX-880 and IND-enabling studies for the encapsulated islet cell program, including anticipated regulatory filings in 2022, and (iv) our plans for dosing and enrollment of patients. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from one patient may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its compounds due to safety, efficacy, and other risks listed under the heading Risk Factors in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at http://www.sec.gov and available through the company's website at http://www.vrtx.com. You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
- Here's Why Longeveron Is Surging Today - Motley Fool - December 4th, 2021
- Global Regenerative Medicine Partnering Report/Directory 2021: Terms and Agreements for 1600 Deals 2014-2 - Benzinga - December 4th, 2021
- CAR T-Cell Therapy Market is anticipated to reach US$ 2.8 Bn by 2031 - PRNewswire - December 4th, 2021
- Stem-cell implant prototypes pave the way towards life-long treatment for type 1 diabetes - ZME Science - December 3rd, 2021
- Certain Patients With Heart Failure May Benefit From Stem Cell Therapy - Pharmacy Times - December 3rd, 2021
- Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update - Yahoo Finance - December 3rd, 2021
- Roundtable Discussion: Usmani and Participants Review Using Transplant and Combination Therapy in a Patient With Newly Diagnosed Multiple Myeloma -... - December 3rd, 2021
- Hematopoiesis and innate immunity: an inseparable couple for good and bad times, bound together by an hormetic relationship - DocWire News - December 3rd, 2021
- Reality of universal cancer prevention & cure - BSA bureau - December 3rd, 2021
- World Aids Day Improving the lives of everyone affected by HIV - QMUL - December 3rd, 2021
- Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of... - December 3rd, 2021
- AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and... - November 28th, 2021
- The questions surgical robots still need to answer - Becker's Orthopedic & Spine - November 24th, 2021
- Holiday Gift Guide 2021: The Best Wellness And Self-Care Essentials For Travel - Forbes - November 24th, 2021
- Investigating pathogens and their life cycles, for the benefit of society - MIT News - November 24th, 2021
- Mitigating Toxicities Will Position BCMA for Role in Triple-Class Refractory Multiple Myeloma - OncLive - November 24th, 2021
- Human Primary Cells Market 2021 | Know the Latest COVID19 Impact Analysis and Strategies of Key Players: Lonza, Thermo Fisher Scientific,... - November 21st, 2021
- Researcher Works for Diversity, Inclusion in Sciences, One Journal at a Time - Lab Manager Magazine - November 18th, 2021
- Raw Marijuana Won't Get You Stoned, But It Does Have Some Interesting Benefits - Benzinga - Benzinga - November 16th, 2021
- The 18 Best New November 2021 Skin-Care Launches That Deserve a Spot in Your Routine - Allure - November 16th, 2021
- Singapore Aims To Lead The World In Lab-Grown Meat - Intelligent Living - November 16th, 2021
- Dermarolling Your Scalp Is Proven to Increase Hair Growth and Thickness Here's How to Do It - Yahoo Lifestyle - November 15th, 2021
- Stem Cell Therapy for Heart Failure Reduces CV Events, Death in Select Patientsbut not Hospitalization - AJMC.com Managed Markets Network - November 15th, 2021
- JASPER THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com - November 15th, 2021
- Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million - Seeking Alpha - November 15th, 2021
- Beam gets green light to begin first clinical test of base editing - BioPharma Dive - November 15th, 2021
- GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and Exposition - Galveston County... - November 15th, 2021
- Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference - GlobeNewswire - November 11th, 2021
- Biotech Companies are Expanding the Frontiers of Engineered Cell Therapy - BioSpace - November 11th, 2021
- Fate Therapeutics Announces Abstract Highlighting FT538 and - GlobeNewswire - November 11th, 2021
- Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer... - November 11th, 2021
- Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress - KULR-TV - November 11th, 2021
- Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference - Yahoo Finance - November 9th, 2021
- CELLECTAR BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com - November 9th, 2021
- Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic - PRNewswire - November 9th, 2021
- Technology set to redesign the future of food as agriculture moves towards net zero - ABC News - November 9th, 2021
- MAGENTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - marketscreener.com - November 5th, 2021
- Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology... - November 5th, 2021
- 15 Best Peptide Skin-Care Products 2021 for Smoother, Firmer, and Plumper Skin - Allure - November 5th, 2021
- Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of... - November 5th, 2021
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results - GlobeNewswire - November 5th, 2021
- Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting - The Bakersfield Californian - November 5th, 2021
- STEMTECH CORPORATION (OTC:GNTW) ANNOUNCES APPOINTMENT OF SANDRA KAZICKAITE TO THE ROLE OF VICE PRESIDENT OF GLOBAL PERFORMANCE - Yahoo Finance - November 3rd, 2021
- Assessing the benefits of stem cell research (column) - LNP | LancasterOnline - November 1st, 2021
- How to Test for Leukemia: What Are My Options? - Healthline - November 1st, 2021
- Exposed: The Plague Of Fake Medical Trials Putting Lives In Danger - Todayuknews - Todayuknews - November 1st, 2021
- To Reduce Stress and Boost Energy, Try Maca Root - The Beet - November 1st, 2021
- In Vitro Toxicology Testing Market Outlook 2021 Pricing Strategy, Industry Latest News, Top Company Analysis, Research Report Analysis and Share by... - November 1st, 2021
- Geron Enters New Innovative Licensing and Access Pathway in the United Kingdom for Imetelstat - Business Wire - November 1st, 2021
- Stem Cell Diseases: What Can Stem Cells Cure | stemcela.com - October 30th, 2021
- The Cost Of Stem Cell Therapy in 2021 | BioInformant - October 30th, 2021
- NIH Guidelines for Human Stem Cell Research | STEM Cell ... - October 30th, 2021
- Fi Europe 2021 innovation finalists mirror mega trends of plant based and sustainability - FoodNavigator.com - October 30th, 2021
- Types of Oncology Drugs - Healthline - October 28th, 2021
- Medical Innovation In Pet Healthcare Is Taking Things Up a Notch - Entrepreneur - October 28th, 2021
- BIOHAVEN ENROLLS PHASE 1A/1B CLINICAL TRIAL OF BHV-1100, LEAD ASSET FROM ITS ARM (ANTIBODY RECRUITING MOLECULE) PLATFORM, IN COMBINATION WITH NK CELL... - October 28th, 2021
- Researchers discover a way to increase the effectiveness of antibiotics - EurekAlert - October 28th, 2021
- Fresh Bros: Exploring the Top Five Health Benefits of Turmeric Extract with BioPerine - GlobeNewswire - October 28th, 2021
- All hopes to save the northern white rhinos now rest on a single female - ZME Science - October 23rd, 2021
- AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1 - StreetInsider.com - October 21st, 2021
- CDMO: The Rise of End-to-End Services - Marketscreener.com - October 21st, 2021
- MeiraGTx Announces the Presentation of Two Novel Inherited - GlobeNewswire - October 21st, 2021
- Current status of drug repositioning in hematology - DocWire News - October 19th, 2021
- Is Fresh Breast Milk Better for Preemies Than Pumped and Stored? - UMass News and Media Relations - October 19th, 2021
- Headband Could Beat Insomnia By Zapping The Brain While Sufferers Wear It For 20 Minutes At Bedtime - - Todayuknews - October 19th, 2021
- BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization -... - October 17th, 2021
- Misinformation on stem cell treatments for COVID-19 linked to overhyped science, researchers argue - EurekAlert - October 17th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - BioSpace - October 17th, 2021
- Nic Chapman: my MS battle and the treatment that's given me hope - The Times - October 17th, 2021
- Dream Body Clinic Stem Cell Therapy Stem Cells HGH - October 13th, 2021
- Hematopoietic Stem Cells - October 13th, 2021
- 3D printing: Healthcare insiders' view on the tech - Verdict - October 13th, 2021
- Top 10 Best Stem Cell Supplement Brands - Healthtrends - October 13th, 2021
- Mitochondrial superoxide dismutase overexpression and low oxygen conditioning hormesis improve the performance of irradiated sterile males |... - October 13th, 2021
- Researchers uncover how cancer cells use sugar residue to evade the immune system - News-Medical.net - October 13th, 2021
- The science and practicality of cultured meat The Stute - The Stute - October 11th, 2021
- Vitro Biopharma Inc. July 31st 2021; 3rd Quarter ended Financial Results of Operations and Shareholder Le - Benzinga - October 11th, 2021
- Want To Support Healthy Bones? It's Time To Get Your Vitamin D In Check - mindbodygreen.com - October 11th, 2021
- Joint : Why Breast Cancer Awareness Matters, and How to Get It Done - marketscreener.com - October 11th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - KY3 - October 7th, 2021